|
| 循环肿瘤细胞检测新技术的构建及其在小细胞肺癌诊断中的应用评估 |
| Development and Evaluation of a Novel Circulating Tumor Cell Detection Technology in the Diagnosis of Small Cell Lung Cancer |
| 投稿时间：2024-11-09 修订日期：2025-03-18 |
| DOI： |
|
 |
| 中文关键词: 小细胞肺癌 循环肿瘤细胞 DLL3 纳米球 |
| 英文关键词:SCLC CTC DLL3 nanometer balls |
| 基金项目:中国国家自然科学基金(批准号81802980)、湖北省杰出青年科学基金(2023AFA079)、白求恩慈善基金会(STLKY2-087) |
|
| 摘要点击次数: 35 |
| 全文下载次数: 0 |
| 中文摘要: |
| [目的]本研究旨在探索一种新型的靶向DLL3的多功能纳米球在小细胞肺癌（SCLC）中循环肿瘤细胞（CTC）的检测效率和特异性，以期提供一种新的诊断方法和靶点，改善SCLC患者的预后。[方法]通过免疫荧光染色和流式细胞术验证了DLL3在SCLC细胞株中的高表达，并使用抗体修饰的磁性纳米球（MNs）捕获CTC。构建了靶向DLL3的多功能纳米微球，并在SCLC细胞系和临床血液样本中测试了其检测CTC的可行性和特异性。此外，还在模拟临床样本和实际患者样本中评估了DLL3-MNs的捕获效率和特异性。[结果]研究结果表明DLL3在SCLC细胞株中高表达，而在正常淋巴细胞和非SCLC细胞株中表达较低。DLL3-MNs在模拟临床样本和实际患者样本中展现了高捕获效率和特异性，与EpCAM-MNs相比，DLL3-MNs显示出更高的特异性和相似的捕获效率。[结论] DLL3-MNs作为一种新型的CTC捕获技术，能够有效且特异性地从SCLC患者血液中捕获CTC，为SCLC的诊断和治疗提供了新的策略。这一方法的进一步优化有望深化我们对SCLC病理机制的认识，并推动新型生物标志物的发现和靶向治疗的进展。 |
| 英文摘要: |
| [Objective] This study aims to investigate the detection efficiency and specificity of a novel DLL3-targeted multifunctional nanoparticle for circulating tumor cells (CTCs) in small cell lung cancer (SCLC), with the goal of providing a new diagnostic method and target to improve the prognosis of SCLC patients.[Methods] High expression of DLL3 in SCLC cell lines was confirmed using immunofluorescence and flow cytometry. Antibody-conjugated magnetic nanoparticles (MNs) were utilized to capture CTCs. A DLL3-targeted multifunctional nanoparticle was constructed and its feasibility and specificity in detecting CTCs in SCLC cell lines and clinical blood samples were tested. Additionally, the capture efficiency and specificity of DLL3-MNs were evaluated in simulated clinical samples and actual patient samples.[Results] The study demonstrated high DLL3 expression in SCLC cell lines, with low expression in normal lymphocytes and non-SCLC cell lines. DLL3-MNs exhibited high capture efficiency and specificity in both simulated and actual patient samples, showing greater specificity and similar capture efficiency compared to EpCAM-MNs.[Conclusion] DLL3-MNs, as an innovative CTC capture technology, can effectively and specifically capture CTCs from the blood of SCLC patients, offering a new strategy for SCLC diagnosis and treatment. Further optimization of this method is expected to deepen our understanding of SCLC pathogenesis and advance the discovery of novel biomarkers and targeted therapies. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |